|1.||Kaul, Sunil C: 3 articles (03/2012 - 08/2002)|
|2.||Wadhwa, Renu: 3 articles (03/2012 - 08/2002)|
|3.||Widodo, Nashi: 2 articles (03/2012 - 07/2007)|
|4.||Maruta, H: 2 articles (12/2000 - 05/2000)|
|5.||Ithychanda, Sujay S: 1 article (06/2014)|
|6.||Schlanger, Simon E: 1 article (06/2014)|
|7.||Cowan, J A: 1 article (06/2014)|
|8.||Luo, Wen-I: 1 article (06/2014)|
|9.||Dare, Michelle: 1 article (06/2014)|
|10.||Emerson, Corey C: 1 article (06/2014)|
01/01/1998 - "Our study finally led us to the identification of compound 3 (MKT 077, 1-ethyl-2-[[3-ethyl-5-(methylbenzothiazolin-2-ylidene)-4-oxothi azolidin-2 -ylidene]methyl]pyridinium chloride) as the candidate for clinical trials and is currently subjected to further investigation as a potent antitumor agent in phase I clinical trial for the treatment of solid tumors."
11/01/2003 - "MKT-077 has been reported to inhibit the growth of several tumor types and has undergone phase I clinical testing. "
11/01/2003 - "MKT-077, a delocalized lipophilic cation, selectively targets cancer cells. "
12/15/2000 - "Thus, MKT-077 may be particularly useful for therapy of cancers with wild-type p53."
12/15/2000 - "In cancer cells, but not in normal cells, MKT-077 induced release of wild-type p53 from cytoplasmically sequestered p53-mot-2 complexes and rescued its transcriptional activation function. "
01/01/2012 - "Uptake rate of cationic mitochondrial inhibitor MKT-077 determines cellular oxygen consumption change in carcinoma cells."
05/01/2000 - "A rhodacyanine dye called MKT-077 has shown a highly selective toxicity toward several distinct human malignant cell lines, including bladder carcinoma EJ, and has been subjected to clinical trials for cancer therapy. "
01/01/1999 - "MKT-077 (1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4- oxothiazolidin-2-ylidenemethyl] pyridinium chloride), a novel rhodacyanine dye in phase I/II clinical trials, may provide a new approach to cancer therapy based on the accumulation in the mitochondria of the cells of certain carcinomas, for example, those of the colon, breast and pancreas. "
|3.||Phototoxic Dermatitis (Phototoxicity)
01/01/1998 - "In this study, the mitochondrial phototoxicity of the cationic rhodacyanine MKT-077 was investigated by comparing its effects on the inhibition of mitochondrial respiration and the structural integrity of mitochondrial DNA (mtDNA) in the presence and absence of added high-intensity visible light (7.5 J/cm2). "
01/01/1998 - "Evaluation of light-induced MKT-077 lipid peroxidation in mitochondrial membrane fragments by the thiobarbituric acid test and by measurement of nonrespiratory-linked oxygen uptake suggests that mitochondrial phototoxicity by MKT-077 may be the result of lipid peroxidation via reactive oxygen species. "
|4.||Colonic Neoplasms (Colon Cancer)
11/01/2003 - "The sensitivity of MDA-PCA-2B cells, the two breast and four colon cancer cell lines to MKT-077 was relatively low (>2.5 microg/ml MKT-077 required to inhibit growth by 95%). "
03/01/1998 - "Co-4 (human colon cancer), St-4 (human gastric cancer), and CRL1420 (human pancreatic cancer) were evaluated as sensitive to MKT-077 in tested 5 strains. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
|1.||Actins (F Actin)
|6.||Coloring Agents (Dyes)
|8.||Mitochondrial DNA (mtDNA)
|1.||Heterologous Transplantation (Xenotransplantation)